z-logo
open-access-imgOpen Access
Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation
Author(s) -
Jianqiang Wu,
Vincent W. Keng,
Deanna M. Patmore,
Jed J. Kendall,
Ami V. Patel,
Edwin Jousma,
Walter J. Jessen,
Kwangmin Choi,
Barbara R. Tschida,
Kevin A.T. Silverstein,
Danhua Fan,
Eric Schwartz,
James R. Fuchs,
Yuanshu Zou,
MiOk Kim,
Eva Dombi,
David E. Levy,
Gang Huang,
José A. Cancelas,
Anat StemmerRachamimov,
Robert J. Spinner,
David A. Largaespada,
Nancy Ratner
Publication year - 2016
Publication title -
cell reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.264
H-Index - 154
eISSN - 2639-1856
pISSN - 2211-1247
DOI - 10.1016/j.celrep.2016.01.074
Subject(s) - wnt signaling pathway , biology , cancer research , catenin , carcinogenesis , neurofibroma , insertional mutagenesis , gene knockdown , context (archaeology) , genetics , microbiology and biotechnology , signal transduction , neurofibromatosis , gene , mutant , paleontology
To identify genes and signaling pathways that initiate Neurofibromatosis type 1 (NF1) neurofibromas, we used unbiased insertional mutagenesis screening, mouse models, and molecular analyses. We mapped an Nf1-Stat3-Arid1b/β-catenin pathway that becomes active in the context of Nf1 loss. Genetic deletion of Stat3 in Schwann cell progenitors (SCPs) and Schwann cells (SCs) prevents neurofibroma formation, decreasing SCP self-renewal and β-catenin activity. β-catenin expression rescues effects of Stat3 loss in SCPs. Importantly, P-STAT3 and β-catenin expression correlate in human neurofibromas. Mechanistically, P-Stat3 represses Gsk3β and the SWI/SNF gene Arid1b to increase β-catenin. Knockdown of Arid1b or Gsk3β in Stat3(fl/fl);Nf1(fl/fl);DhhCre SCPs rescues neurofibroma formation after in vivo transplantation. Stat3 represses Arid1b through histone modification in a Brg1-dependent manner, indicating that epigenetic modification plays a role in early tumorigenesis. Our data map a neural tumorigenesis pathway and support testing JAK/STAT and Wnt/β-catenin pathway inhibitors in neurofibroma therapeutic trials.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom